A cross-sectional study on the drug usage of insomnia in the Chinese medicine hospital in Long gang, Shenzhen

Jingfeng Lin^{#a}, Zhenyi Wang^{#a}, Danfeng Tian^{#a}, Run Xi^b, Zhenyun Han^b

These authors contribute equal to this work

a Beijing University of Chinese Medicine, Beijing, 100029, China

b Shenzhen Hospital of Beijing University of Chinese Medicine (Longgang), Shenzhen, 518100, China

*Corresponding Author:

Zhenyun Han

Shenzhen Hospital of Beijing University of Chinese Medicine (Longgang), 1 Dayun road ,

Longgang district, Shenzhen, 518100, China

Tel: +86- 13581647676

E-mail: tohanzhenyun@sina.com

Abstract

Introduction

Insomnia was widely distributed among the population, and it was a risk factor for many diseases. To evaluate the condition of usage of drugs in Chinese hospital of Longgang, Shenzhen, we carried this cross-sectional research. We extracted the information of drug usage, symptoms of patients by R software (version 4.0.2) from Hospital Information System (HIS). The research was registered in Chinese Clinical Trial Registry, ChiCTR2000040703.

Methods

A retrospective, cross-sectional study was conducted in Shenzhen Hospital of Beijing University of Chinese Medicine (Long Gang). Insomnia patients from Jan 1, 2016 to Nov 10, 2020 were included to cross-sectional study. We analyzed the basic information, the condition of drug usage and the relation of symptoms and drug usage by R software (version 4.0.2).

Results

Totally 9439 patients were included in the study. The average age of these patients was 45.81years (SD 13.97 years). Anxiety, dreaminess, dizzy, palpitation, headache, thirsty, weakness, chest distress, annoyance, abdominal distension, bad moods, difficulty falling asleep and bitter taste were core symptoms of insomnia. Totally 14256 times (67.65%) patients received drug prescription and more than one insomnia drug was administered in 8355 patients. The 10 most used drugs ranged from more to less were Estazolam(29.99%), Zaoren Anshen Capsule(15.50%), Oryzanol(14.82%), Diazepam(14.51%), Flupentixol and Melitracen(14.30%), Alprazolam(8.12%), Zolpidem Tartrate(5.29%), vitamin B6(4.76%), Sertraline(4.03%), Clonazepam(2.97%).

Conclusion

The drug usage for insomnia in the Chinese medicine hospital in Long gang, Shenzhen were mainly included benzodiazepine, nonbenzodiazepine, Chinese patent medicines, anti-anxiety and anti-depression drugs, oryzanol and vitamin B6. The usage of Oryzanol and vitamin B6 should be abused in Chinese medicine hospital, and the usage of Chinese medicine should be more rigorous evaluated. The nonbenzodiazepine should be promoted and broader understood in Chinese medicine hospital in Longgang, Shenzhen.

Key words: Shenzhen, insomnia, drug usage

1.Introduction

Insomnia is broadly defined as dissatisfaction with sleep either qualitatively or quantitatively¹. The rates of insomnia varied from 6%-19%^{2,3}. Classical benzodiazepines and benzodiazepine receptor agonists (BZRAs, Nonbenzodiazepines; zopiclone, zolpidem, and zaleplon) are used in managing insomnia, but antidepressants are also used in clinical practice, although there is less evidence of their efficacy⁴. In addition, antipsychotics, antihistamines, phytotherapeutic substances and melatonin were also used as the therapeutic regimen for insomnia with lower evidence². Insomnia could be a risk factor for cardiovascular diseases⁵⁻⁷, arterial hypertension, myocardial infarction, chronic heart failure^{8,9}, type 2 diabetes¹⁰ and obesity and hypertension¹¹. So, a big data analysis on the drug usage of insomnia was very necessary to help evaluating the reasonableness of it. In China, to evaluate the condition of usage of drugs in Longgang Shenzhen, we carried this cross-sectional research. We extracted the information of drug usage, symptoms of patients by R software (version 4.0.2) from Hospital Information System (HIS). The association rules analysis was carried to find out the relationship with symptoms and usage of drugs. The research was registered in Chinese Clinical Trial Registry, ChiCTR2000040703.

2. Methods

2.1 Study setting and patients

A retrospective, cross-sectional study was conducted in Shenzhen Hospital of Beijing University of Chinese Medicine(Long Gang). Insomnia patients from Jan 1, 2016 to Nov 10, 2020 were included to cross-sectional study. The included criteria were: (1) International Classification of Sleep Disorders (ICSD-3) Diagnostic Criteria for short-term and chronic insomnia. (2) We excluded patients that were of mental or nervous system dysfunction, or unable to express willingness. This study was approved by the ethics committee of Shenzhen Hospital of Beijing University of Chinese Medicine(Long Gang).

2.2 Data collection and analysis

The information of patient, medication, and microbiologic examination, including register number, age, sex, diagnosis, admission time were collected from Shenzhen Hospital of Beijing University of Chinese Medicine Hospital Information System (HIS) by clinical practitioners. Data were analyzed by R software(version 4.0.2).

3. Results

3.1 Baseline patient characteristics

Totally 9439 patients were included in the study, with 21073 times coming to the doctors, among who 3470 (39.6%) were male, and 5699 (60.4%) were female. With there were 6577 patients (69.7%) and 14256(67.7%) times coming included in the retrospective cross-sectional study to assess the drug use. The average age of these patients was 45.81years (SD 13.97 years). Table 1 shows the characteristics of 9439 included patients.

Table 1: The characteristics of 9439 included patients

	All	Male	female	P-value
Average age				
Mean (SD)	45.81 (±13.97)	45.28 (±13.92)	46.16 (±14.00)	0.001
Agegroup				

	All	Male	female	P-value
≤30	1154 (12.23%)	456 (39.51%)	698 (60.49%)	0.0005
31-45	3740 (39.63%)	1573 (42.06%)	2167 (57.94%)	
46-60	3050 (32.32%)	1164 (38.16%)	1886 (61.84%)	
>60	1493 (15.82%)	547 (36.64%)	946 (63.36%)	

*Excluded the patients with no information of age

3.2 Use of benzodiazepine

Table 2: Use of benzodiazepine

Drugs	Frequency	Rates
Estazolam	4276	29.99%
Diazepam	2069	14.51%
Alprazolam	1157	8.12%
Clonazepam	424	2.97%

Among the total of 21073 times, 14256 times (67.65%) patients received drug prescription and more than one insomnia drug was administered in 8355 patients. Among the patients using with benzodiazepines, 4276(29.99%) patients received estazolam, 1157(8.12%) patients received Alprazolam, 2069(14.51%) patients received Diazepam,. Among the 754(5.29%) patients received Zolpidem Tartrate, 424(2.97%) patients received Clonazepam.

3.3 Use of nonbenzodiazepine

Table 3: Use of nonbenzodiazepine

Drugs	Frequency	Rates
Zolpidem Tartrate	754	5.29%
Dexzopiclone	119	0.83%

Among the patients using with nonbenzodiazepines, 754(5.29%) patients received Zolpidem Tartrate, 119(0.83%) patients received Dexzopiclone.

3.4 Use of Chinese patent medicines

Table 4: Use of Chinese patent medicines

Drugs	Frequency	Rates
Zaoren Anshen Capsule	2209	15.50%
Shumian Capsule	400	2.81%

Totally 2209(15.50%) patients received Zaoren Anshen Capsule and 400 (2.81%) patients received Shumian Capsule.

3.5 Use of traditional Chinese medicines

Among 4406(30.91%) comings used traditional Chinese medicines.

3.6 Use of anti-anxiety and anti-depressants

Among the all patients, 2038 (14.3%) were given Flupentixol and Melitracen. And of the 575(4.03%) patients took Sertraline.

Table 5: Use of anti-anxiety and anti-depressants

Drugs	Frequency	Rates
Flupentixol and Melitracen	2038	14.30%
Sertraline	575	4.03%
Escitalopram	120	0.84%

102 3.7 Use of other kinds of medicine

103 Among the all patients, 2113 (14.82%) were given Oryzanol. And of the 679(4.76%) patients
104 took Vitamin B6.

105

106

Table 6: Other kinds of medicine

Drugs	Frequency	Rates
Oryzanol	2113	14.82%
vitamin B6	679	4.76%

107

108 3.8 Symptoms collection

109 A total of 17,337 outpatient electronic medical records (EMRs) were obtained by screening
110 the included patient, and the retention of EMRs accounted for 82.27% of the total number of
111 patients. The R software stringr package was used to extract the symptoms and signs information
112 contained in the medical records. The extracted symptom and sign information results were sorted
113 in descending order. The top 20 symptoms were selected, and the results were as follows:

114

Table 7: Top 20 symptoms of insomnia

Symptoms	Freq	Rates
Anxiety	3803	21.94%
Dreaminess	2883	16.63%
Dizzy	2063	11.90%
Palpitation	1985	11.45%
Headache	1867	10.77%
Upset	1694	9.77%
Thirsty	1681	9.70%
Weakness	1659	9.57%
Chest distress	1538	8.87%
Annoyance	1143	6.59%
Abdominal distension	1138	6.56%
Difficulty falling asleep	1123	6.48%
Bitter taste	1108	6.39%
Bad moods	978	5.64%

Constipation	464	2.68%
Soreness of waist	443	2.56%
Eat less	365	2.11%
Lambago	272	1.57%
Loose stool	212	1.22%
Tinnitus	189	1.09%
Short of breath	148	0.85%
Dry throat	134	0.77%
Irritable	125	0.72%
Early awaking	118	0.68%
Idrosis	101	0.58%

115 From Table 7, we could conclude that anxiety, dreaminess, dizzy, palpitation, headache,
116 thirsty, weakness, chest distress, annoyance, abdominal distension, bad moods, difficulty falling
117 asleep and bitter taste were core syndromes of insomnia.

118 3.9 Reinteraction of symptoms and drugs

119 We select the patients using benzodiazepine, nonbenzodiazepine, Chinese patent medicines,
120 oryzanol and vitamin B6 respectively, anti-anxiety and anti-depressants and summary the times of
121 syndromes appearing in the patients. The results were as following:

122 Table 8: Different kinds of drugs and its main symptoms

Kinds of drugs	Symptoms	Freq	Rates
Benzodiazepine			
	Anxiety	2310	31.35%
	Dreaminess	1030	13.98%
	Palpitation	611	8.29%
	Dizzy	572	7.76%
	Upset	527	7.15%
	Headache	513	6.96%
	Weakness	498	6.76%
	Chest distress	482	6.54%
	Difficulty falling asleep	408	5.54%
	Dry throat	392	5.32%
Nonbenzodiazepine			
	Anxiety	187	21.59%
	Dreaminess	105	12.12%
	Difficulty falling asleep	95	10.97%
	Palpitation	88	10.16%
	Headache	84	9.70%

	Upset	78	9.01%
	Dizzy	78	9.01%
	Chest distress	73	8.43%
	Weakness	72	8.31%
	Abdominal distention	60	6.93%
Chinese patent medicines			
	Dreaminess	355	20.89%
	Palpitation	279	16.42%
	Anxiety	261	15.36%
	Dizzy	205	12.07%
	Abdominal distention	195	11.48%
	Headache	194	11.42%
	Chest distress	174	10.24%
	Weakness	156	9.18%
	Dry throat	126	7.42%
	Upset	120	7.06%
Oryzanol and vitamin B6			
	Anxiety	1192	52.74%
	Dreaminess	728	32.21%
	Upset	192	8.50%
	Headache	151	6.68%
	Dizzy	104	4.60%
	Bad moods	103	4.56%
	Weakness	97	4.29%
	Bitter taste	87	3.85%
	Dry throat	75	3.32%
	Difficulty falling asleep	74	3.27%
Anti-anxiety and anti-depressants			
	Anxiety	1466	60.06%
	Dreaminess	564	23.11%
	Bad moods	539	22.08%
	Upset	376	15.40%
	Dizzy	205	8.40%
	Difficulty falling asleep	200	8.19%
	Headache	176	7.21%
	Palpitation	172	7.05%
	Weakness	140	5.74%
	Dry throat	103	4.22%

123 For the patients who received benzodiazepine, nonbenzodiazepine, Oryzanol and vitaminB6,
124 and Anxiety and depression, most common symptom was Anxiety. However, for Chinese patent
125 medicines, most common symptom was Dreaminess.
126 Association rules analysis was carried for various symptoms and different kinds of drugs by

arules package, R software. In the analysis of association rules of kinds of drugs and symptoms, we selected association rules of support degree >0.01 and confidence degree >0.1 to find the association rules between benzodiazepine and symptoms, and we selected association rules of support degree >0.005 and confidence degree >0.05 to find the association rules between Chinese patent medicines, Oryzanol and Vitamin, Anti-anxiety and anti-depressants and symptoms. We also found that there were no significant association rules between Nonbenzodiazepines and symptoms. The aruleViz package was used to draw the correlation diagram, and the results were shown in Figure 1.

Figure 1: Association rules analysis of drug usage and symptoms

The results showed that patients received benzodiazepines were associated with Anxiety, Dreaminess, Upset, Bitter taste, Difficulty falling asleep, Chest distress, Palpitation, Weakness, Headache, Dizzy, Thirsty, Abdominal distension, which were in accordance with the result in Table. Patients received Chinese patent medicines were associated with Dizzy, Weakness, Dreaminess, palpitation, chest distress and headache. Patients received Oryzanol and Vitamin were associated with Headache, anxiety, dreaminess and upset. Patients received anti-anxiety or anti-depression drugs were associated with anxiety, bad mood, upset, dizzy, dreaminess and headache.

4. Discussion

This study evaluates the drug use in treating the patients in Longgang, Shenzhen, who suffered from insomnia by Hospital Information System (HIS) in Shenzhen Hospital of Beijing University of Chinese Medicine(Long Gang). About 9439 patients were included in the study, with 21073 times coming to the doctors to assess the rationality of drug use and the majority of them are female(60.4%). The results demonstrate that benzodiazepine, nonbenzodiazepine, traditional Chinese medicines, Oryzanol and vitaminB6 are the principal drugs to treat insomnia in patients. Anti-anxiety and anti-depression are the main prescript drugs for insomnia with the symptoms of anxiety and depression.

In European insomnia guideline, the Benzodiazepines, benzodiazepine receptor agonists and some antidepressants are effective in the short term treatment of insomnia, and phytotherapeutics are not recommended for insomnia treatment². In our research, we found that Chinese patent medicines(18.31%) and traditional Chinese medicines(30.91%) were widely used in Shenzhen Hospital of Beijing University of Chinese Medicine(Long Gang), which was contradicted to the guidelines. In other cross-sectional about drug usage for insomnia, Suzanne M. Bertisch³ did not reported the usage of phytotherapeutics in a big cross-sectional research of Prescription Medications for Insomnia in America. In past research, there were no significant evidence on the efficacy of phytotherapeutics for insomnia. Xiaojia Ni¹² made a meta-analysis on efficacy of Chinese medicine on insomnia compared with placebo, and found that the Chinese medicine was better than placebo, however, the quality of included studies was pool². So, we thought the efficacy of Chinese medicine on insomnia and the rationality of drug use in Shenzhen Hospital of Beijing University of Chinese Medicine(Long Gang) should be further evaluated.

For benzodiazepine and nonbenzodiazepine, a meta-analysis indicated that there were no difference between them¹³. In our research, we found that the usage of benzodiazepine was far more than nonbenzodiazepine, the reason we thought was the benzodiazepines were more acceptable in Longgang, Shenzhen doctors.

For Oryzanol and vitamin B6, there were about 14.82% patients received Oryzanol and about 4.76% patients received vitamin B6. In past research, there were no significant evidence indicated that Oryzanol could be helpful to insomnia, and it didn't be recommended in guideline¹³. For vitamin B6, Patrick Lemoine¹⁴ found that the combination of melatonin, vitamin B6, and medicinal plants may be beneficial in mild-to-moderate insomnia. However, there were no single-evidence for vitamin B6 about whether it was effective for insomnia.

Alexander Winkler¹⁵ made an analysis on antidepressant drugs and found that the efficacy of antidepressants was weaker than that for benzodiazepines and nonbenzodiazepines, other researches indicated that adverse effects and study withdrawals did not significantly differ between participants receiving doxepin and those receiving placebo¹⁶. In our research, Flupentixol and Melitracen and sertraline were mostly used in Beijing University of Chinese Medicine(Long Gang). For Flupentixol and Melitracen on insomnia, a research from China also reported the Flupentixol and Melitracen was widely used in 20 national hospitals of China, however, there was no precise evidence manifested the Flupentixol and Melitracen was effective to insomnia and was not be recommended in guideline².

For sertraline, there were some evidence indicated that Antidepressant Pharmacotherapy could relief the symptoms in Patients With Comorbid Depression and Insomnia¹⁷ and the efficiency was exactly².

For the relationship between symptoms and different kinds of drugs, we would find that antidepressant and anti-anxiety drugs were related to Anxiety, bad moods and dreaminess, and Chinese patent medicines were more concretely about dreaminess, which indicated that the usage of antidepressant and Chinese patent medicines was Symptom-related.

To improve the construction drug usage in Shenzhen, Longgang, we thought that the use of Chinese patent medicine and Chinese medicine should be evaluated more carefully. As it was well known that in Chinese medicine hospital in China, there were much Chinese medicine and Chinese patent medicine used than Western medicine hospital in China. However, the usage of Chinese medicine was lack of proper efficacy evaluation and clinical trial or observation with high level evidence². The more rigorous, high-quality clinical trials should be carried to evaluate the exact efficacy in specific patients. In addition, we thought the nonbenzodiazepine had some advantages than benzodiazepine and should be promoted in Chinese medicine hospital.

For the deficiencies of this research, the data of research was from the HIS by R software, for some clinician would omit or miswrite some information by the busy work, the data could be some biases and the data maybe have some incompleteness. P. W. Handayani¹⁸ pointed that the HIS still needs to be refined in terms of providing optimal health services in development countries, and there was considerable dissatisfaction with the quality of the existing HIS among doctors. In addition, the information of patients in HIS of Chinese medicine hospital, Longgang, Shenzhen were mainly about sex, age, other important information was not recorded. So, as a sectional study, the information collection was inadequate.

In conclusion, the drug usage for insomnia in the Chinese medicine hospital in Long gang, Shenzhen were mainly included benzodiazepine, nonbenzodiazepine, Chinese patent medicines, anti-anxiety and anti-depression drugs, Oryzanol and vitaminB6. The usage of Oryzanol and vitaminB6 should be abused in Chinese medicine hospital, and the usage of Chinese medicine should be more rigorous evaluated. The nonbenzodiazepine should be promoted and broader understood in Chinese medicine hospital in Longgang, Shenzhen.

Abbreviations

HIS: Hospital Information System; BZRA: Benzodiazepine receptor agonist.

Declarations

Statement of Ethics

The experiment was approved by Ethic committee of Shenzhen Hospital of Beijing university of Chinese medicine.

Availability of data and materials

The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

Conflict of Interest Statement

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Funding

This work is funded by National Key Research and Development Plan(SQ2019YFC170218).

Authors' contributions

Jingfeng Lin, Zhenyi Wang and Danfeng Tian performed the integral research. Jingfeng Lin and Run Xi performed data screen and data analysis. Zhenyun Han conceived and supervised the study. Jingfeng Lin, Zhenyi Wang and Danfeng Tian drafted the manuscript. All authors read and approved the final manuscript.

233

234 1. Patel D, Steinberg J, Patel P. Insomnia in the Elderly: A Review. *J Clin Sleep Med*

235 2018;14(6):1017-24. doi: 10.5664/jcsm.7172 [published Online First: 2018/06/02]

236 2. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and

237 treatment of insomnia. *J Sleep Res* 2017;26(6):675-700. doi: 10.1111/jsr.12594

238 [published Online First: 2017/09/07]

239 3. Bertisch SM, Herzig SJ, Winkelman JW, et al. National use of prescription medications for

240 insomnia: NHANES 1999-2010. *Sleep* 2014;37(2):343-9. doi: 10.5665/sleep.3410

241 [published Online First: 2014/02/06]

242 4. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for

243 chronic insomnia in adults: a meta-analysis of RCTs. *J Gen Intern Med*

244 2007;22(9):1335-50. doi: 10.1007/s11606-007-0251-z [published Online First:

245 2007/07/11]

246 5. Li M, Zhang X-W, Hou W-S, et al. Insomnia and risk of cardiovascular disease: A

247 meta-analysis of cohort studies. *International Journal of Cardiology*

248 2014;176(3):1044-47. doi: 10.1016/j.ijcard.2014.07.284

249 6. Sofi F, Cesari F, Casini A, et al. Insomnia and risk of cardiovascular disease: a

250 meta-analysis. *European journal of preventive cardiology* 2014;21(1):57-64.

251 7. Meng L, Zheng Y, Hui R. The relationship of sleep duration and insomnia to risk of

252 hypertension incidence: a meta-analysis of prospective cohort studies. *Hypertension*

253 *Research* 2013;36(11):985-95.

254 8. Palagini L, Maria Bruno R, Gemignani A, et al. Sleep loss and hypertension: a systematic

255 review. *Current pharmaceutical design* 2013;19(13):2409-19.

- 256 9. Laugsand LE, Vatten LJ, Platou C, et al. Insomnia and the risk of acute myocardial infarction:
257 a population study. *Circulation* 2011;124(19):2073-81.
- 258 10. Anothaisintawee T, Reutrakul S, Van Cauter E, et al. Sleep disturbances compared to
259 traditional risk factors for diabetes development: systematic review and meta-analysis.
260 *Sleep medicine reviews* 2016;30:11-24.
- 261 11. Buxton OM, Marcelli E. Short and long sleep are positively associated with obesity,
262 diabetes, hypertension, and cardiovascular disease among adults in the United States.
263 *Soc Sci Med* 2010;71(5):1027-36. doi: 10.1016/j.socscimed.2010.05.041 [published
264 Online First: 2010/07/14]
- 265 12. Ni X, Shergis JL, Guo X, et al. Updated clinical evidence of Chinese herbal medicine for
266 insomnia: a systematic review and meta-analysis of randomized controlled trials.
267 *Sleep Med* 2015;16(12):1462-81. doi: 10.1016/j.sleep.2015.08.012 [published Online
268 First: 2015/11/28]
- 269 13. Dündar Y, Dodd S, Strobl J, et al. Comparative efficacy of newer hypnotic drugs for the
270 short-term management of insomnia: a systematic review and meta-analysis. *Human*
271 *Psychopharmacology: Clinical and Experimental* 2004;19(5):305-22. doi:
272 10.1002/hup.594
- 273 14. Lemoine P, Bablon J-C, Da Silva C. A combination of melatonin, vitamin B6 and medicinal
274 plants in the treatment of mild-to-moderate insomnia: A prospective pilot study.
275 *Complementary Therapies in Medicine* 2019;45:104-08. doi:
276 10.1016/j.ctim.2019.05.024
- 277 15. Winkler A, Auer C, Doering BK, et al. Drug Treatment of Primary Insomnia: A

278 Meta-Analysis of Polysomnographic Randomized Controlled Trials. *CNS Drugs*
279 2014;28(9):799-816. doi: 10.1007/s40263-014-0198-7

280 16. Wilt TJ, MacDonald R, Brasure M, et al. Pharmacologic Treatment of Insomnia Disorder:
281 An Evidence Report for a Clinical Practice Guideline by the American College of
282 Physicians. *Ann Intern Med* 2016;165(2):103-12. doi: 10.7326/M15-1781 [published
283 Online First: 2016/05/03]

284 17. Manber R, Buysse DJ, Edinger J, et al. Efficacy of Cognitive-Behavioral Therapy for
285 Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid
286 Depression and Insomnia: A Randomized Controlled Trial. *J Clin Psychiatry*
287 2016;77(10):e1316-e23. doi: 10.4088/JCP.15m10244 [published Online First:
288 2016/10/28]

289 18. Handayani PW, Hidayanto AN, Pinem AA, et al. Hospital information system user
290 acceptance factors: User group perspectives. *Informatics for Health and Social Care*
291 2017;43(1):84-107. doi: 10.1080/17538157.2016.1269109
292